Aims: Colorectal carcinoma (CRC) with micropapillary (MP) features has only been described recently and is still being characterized.
Introduction
Morphological subtyping of colorectal carcinoma (CRC) is a commonly accepted practice among gastrointestinal pathologists and often carries an impact upon patient prognosis. The 2010 edition of the WHO classification of tumours of the digestive system recognizes six subtypes of CRC: mucinous, signet ring cell, medullary, serrated, cribriform comedo-type and micropapillary (MP). 1 Literature on the latter three subtypes has appeared only in recent years, most notably for MP CRC, a well-recognized subtype of adenocarcinoma in numerous other organ systems, including breast 2 and bladder. 3 Beginning in 2005, several case series [4] [5] [6] [7] [8] [9] [10] [11] and case reports [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] were published on MP CRC, elucidating its clinical behaviour, genetic properties and prognosis. In general, this subtype of colorectal adenocarcinoma presents as locally advanced disease, displays a tendency towards lymphovascular invasion and lymph node metastasis and reportedly imparts a poor prognosis compared to conventional CRC. [5] [6] [7] [8] [9] [10] These findings are in keeping with MP carcinomas reported in other organ systems. 22 While these tumours have not been studied extensively on a genetic level, TP53 and KRAS mutations appear to be frequent, and microsatellite instability (MSI) is very uncommon. 8 Epithelial-mesenchymal transition (EMT) is a multistep dynamic cellular phenomenon in which epithelial cells lose their cell-cell adhesion and gain migratory and invasive traits that are typical of mesenchymal cells. EMT involves loss of membranous localization of the epithelial marker E-cadherin and an increase in levels of one or more mesenchymal markers, such as vimentin, N-cadherin, a-smooth muscle actin or fibronectin, along with a loss of polarized function of epithelial cells. 23, 24 This phenomenon has been associated with increased rate of metastasis in many types of carcinoma 25 and has been implicated in the pathogenesis of CRC. [26] [27] [28] [29] Immunohistochemistry for certain proteins, including E-cadherin, vimentin, Snail, Zeb and Twist, can indicate the occurrence of EMT. [30] [31] [32] We have observed that the interface between tumoral epithelial cells and mesenchymal stromal cells often does not show a clear transition in MP CRC, suggesting the possibility of EMT. To our knowledge, this has only been investigated in one study to date. 33 To further our understanding of this putatively aggressive subtype of CRC, we report our experience analysing them on a clinical, pathological, immunohistochemical and molecular basis.
Materials and methods
With appropriate Institutional Research Board approval, slides from 1003 CRC resections in the institution-restricted research files of the authors were reviewed for MP features anywhere within the tumours. The same criteria for diagnosis of MP carcinoma in other organs were applied; specifically, MP features were defined as areas demonstrating small rounded clusters of malignant epithelial cells with reversed polarity (apical surfaces facing the periphery rather than the center of the tumour cluster), abundant eosinophilic cytoplasm and retraction artefact creating lacunae-like spaces around the micropapillae ( Figure 1A ). Fibrovascular cores were absent. Micropapillae were distinguished from tumour budding using the following criteria: presence within the tumour bulk rather than just the leading edge, composition of more than five cells, well-formed nature (rather than small clusters of cells), reversed polarity, eosinophilia and lacunae. 34 All included tumours were at least 5% MP, as with previous series. [5] [6] [7] [8] 10 Thirty-five CRC patients with at least focal MP features were identified, representing 3.5% of the CRC cases on file. Seven additional cases were identified prospectively or during review of colorectal cancer cases for separate research projects, bringing the total number of cases to 42, each from a different patient.
For each case, all available slides were reviewed along with the original pathology report to determine tumour size, depth of invasion, lymphovascular invasion, perineural invasion, peritumoral chronic inflammation and spread to lymph nodes or distant sites. Patient sex, age and date of resection were recorded, as were date of and vital status at last known followup. Tumours were staged using American Joint Committee on Cancer (AJCC) TNM 7th edition criteria. 35 The percentage of the tumour demonstrating MP features was estimated, and the presence of other identifiable microscopic patterns was noted.
For immunohistochemistry, 4-lm unstained sections from formalin-fixed, paraffin-embedded tissues were first deparaffinized by routine methods. For antigen retrieval, sections were heated to 104°C for 20 min in a pH 6.0 citrate buffer and then allowed to cool to room temperature. Afterwards, tissue sections were quenched with 3% H 2 O 2 in NaN 3 for 5 min at room temperature. Primary antibodies used included anti-SMAD4 (1:100 dilution; Santa Cruz Biotechnology, Dallas, TX, USA), anti-vimentin (1:100 dilution; Dako, Carpinteria, CA, USA), anti-AE1/AE3 (1:100 dilution; Dako) and anti-E-cadherin (1:800; BD Biosciences, San Jose, CA, USA); these four markers were chosen due to our experience regarding their reliability in our laboratory. Immunolocalization was performed using the Dako Envision+ Mutational analysis for KRAS, NRAS, BRAF, PIK3CA, AKT, PTEN and SMAD4 was performed using a laboratory-developed assay. 36 Mutations analysed included AKT1 (codon E17), BRAF (codons G466, G469, D594, G596, V600), KRAS (codons G12, G13, Q61, A146, K117), NRAS (codons G12, Q61), PIK3CA (codons H1047, E542, E545, Q546, D549), PTEN (codons R233, R159, R267) and SMAD4 (codons E330, D351, D355, R361). This panel was chosen based on mutation frequency and relevance to potential targeted therapy in CRC. Results of MSI testing were also available for some tumours.
A cohort of 972 patients with conventional (non-MP) CRC was used as a comparison group. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Student's t-test with unequal variances. The prognostic significance of the MP subtype on disease-specific survival was assessed using a Cox proportional hazards regression model, and risk of death relative to the percentage of tumour with MP features was analysed using logistic regression. Other variables significant in univariate analysis were included with histological type in a subsequent multivariate Cox regression model. All statistical tests were performed using STATA version 13.1 (College Station, TX, USA). All hypothesis tests were two-sided, with a = 0.05.
Results
Clinicopathological findings are summarized in Table 1 . The extent of each tumour composed of MP features averaged 27%; 13 cases demonstrated approximately 5% MP areas while 10 were at least half MP, including one tumour that was entirely MP. The MP component was associated frequently with a dense hypercellular stromal reaction ( Figure 1B ).
The majority of MP cases (27 of 42; 64%) possessed a characteristic morphology elsewhere in the tumour, with numerous cribriform glands and large, dilated glands filled with dirty necrotic debris; MP foci were often distributed focally around these areas (Figure 1C ). Four cases (10%) demonstrated 'pseudo-MP' areas, wherein the nests of tumour cells were confluent rather than discrete, and retraction artefact did not completely surround the nests ( Figure 1D ); classic MP features were present elsewhere in these tumours. In five of the included cases (12%) the MP nests floated in a background of mucin, rather than infiltrating stroma ( Figure 1E ); four other cases had separate, more traditional areas of mucinous D, Some tumours displayed areas of 'pseudo-micropapillary' morphology, with confluence of nests and less retraction artefact. E, Some cases demonstrated micropapillae situated in mucin pools rather than in artefactual spaces. F, Lymph node metastases occasionally showed micropapillary areas, although, more characteristically, they displayed large, cystically dilated glands with prominent dirty necrosis; the malignant lining cells resembled micropapillary areas cytologically but not architecturally.
adenocarcinoma separate from the MP component.
Other minor components seen in some tumours included signet ring areas (one case) and poorly differentiated areas (two cases). Lymphovascular invasion was present in 35 cases (83%). Lymph node metastases were common in MP CRC (74% of cases). Typically, nodal metastases resembled either conventional CRC or appeared as large, cystic spaces filled with dirty necrosis and lined by malignant cells with eosinophilic cytoplasm similar to those seen in the MP component of the primary tumour. However, MP features were present in 10 of the lymph node metastases (32%) ( Figure 1F ).
Twenty-three patients (55%) developed distant metastases (liver, n = 13; omentum, n = 5; peritoneum, n = 5; lungs, n = 2; ovaries, n = 2; small intestine, n = 2; cystic duct lymph node, n = 1). Tissue was available from metastatic lesions in 17 of these patients, with MP areas present in seven (41%).
Molecular analysis targeting specific genetic mutations was performed in 31 of the 42 MP cases. While 14 showed no mutations in the analysed codons, the other 17 (55%) harboured at least one mutation. The most frequently mutated gene was KRAS, with mutations in 11 tumours (35%): G12A (n = 1), G12D (n = 2), G12S (n = 2), G13C n = 1), G13D (n = 4) and Q61H (n = 1). Four cases showed a BRAF V600E mutation; of these, one also harboured a SMAD4 R361H mutation, and one showed a PIK3CA H1047R mutation. The same PIK3CA mutation was evident in one of the cases with a KRAS G12S mutation. Finally, one case showed only a SMAD4 R361H mutation, and one showed only an NRAS Q61L mutation. In three of the analysed cases, the mutational analysis was performed on both cribriform and MP areas separately, with no difference in mutational profile observed. Results of MSI testing were available for 21 cases, of which all were microsatellite-stable. The possibility of EMT was examined in 29 cases by immunohistochemical expression of epithelial and mesenchymal markers and SMAD4 localization. Eighteen of 29 cases (62%) showed focal loss or decrease of AE1/AE3 (Figure 2A) , and membranous E-cadherin was lost focally in 78% of cases (21 of 27; Figure 2B) . Occasional vimentin-positive carcinoma cells were observed in 13 of 29 cases (45%) (Figure 2C ), and 24 of 29 cases (83%) showed at least focal nuclear localization of SMAD4 ( Figure 2D ).
Overall median patient follow-up was 36 months (range: 1-133 months). Seventeen patients (40%) died of disease, all of whom had distant metastases (median length of survival: 23 months). An additional seven patients died of unknown or unrelated causes. The remaining 18 patients were alive at last follow-up, four of whom had distant metastatic disease.
As shown in Table 1 , patients with MP CRC were younger than patients with conventional CRC and more likely to present with stage IV disease. On univariate analysis, larger tumour size, lymphovascular invasion, perineural invasion, lack of peritumoral inflammation and advanced stage (including advanced T-category, N-category and M-category) were associated with shorter disease-specific survival (Table 2) . On multivariate analysis, independent prognostic factors for shorter disease-specific survival included female sex, older age, larger tumour size, lymphovascular invasion, lack of peritumoral inflammation and advanced stage. Stage for stage, MP patients fared similarly to patients with conventional CRC (Figure 3) . Among MP patients, for every 10% increase in MP component within the tumour the risk of disease-specific death decreased by 8.5%, but this was not statistically significant (P = 0.35).
Discussion
Our findings generally agree with those observed in prior case series of MP CRC. Specifically, this CRC subtype tends to present as advanced disease with lymphovascular invasion and distant metastasis. Consequently, a high proportion of patients with this histological subtype die of disease (5-year disease-specific survival of 54%, compared to 67% of conventional CRC in our cohorts). [5] [6] [7] [8] [9] [10] There were, however, some discrepancies between our findings and those reported previously. Whereas we found at least focal MP features in 35 sampling from resection specimens or possibly differences in diagnostic criteria. In addition, while others have observed a tendency for even pT1 or pT2 MP carcinomas to spread to lymph nodes, 6, 7 only one of our pT1 or pT2 cases had nodal metastasis. This may be due to the low numbers of cases in these categories (pT1, n = 4; pT2, n = 2).
Finally, we found that although patients with MP CRC present typically at advanced AJCC stage, they have similar outcomes compared to patients with conventional CRC. Thus, MP features have a limited impact on patient prognosis after adjusting for the confounding effect of advanced tumour stage.
Other studies comparing MP CRC to conventional CRC have reported somewhat incongruous results, including that patients with stages I-II MP CRC fare similarly, if not somewhat worse, than those with stages III-IV disease. 7 While some authors report that MP features are an independent poor prognostic factor in multivariate analysis, 10 others suggest that they are not. 9 That MP CRC is more likely to present at an advanced stage seems clear, but given this variability among reported outcome studies, its overall significance with regard to patient prognosis remains somewhat uncertain.
While MP architecture is somewhat striking and unique, it has a potential histological mimic in tumour budding, 5, 8 a pattern that has come under increased scrutiny during the past few years. Described as 'an isolated single cancer cell or a cluster composed of fewer than five cancer cells', 34 tumour budding is usually present at the invading edge of a carcinoma but has also been reported intratumorally. 37 In situations where the budding tumour cells demonstrate eosinophilic cytoplasm or appear to fill lacunae-like spaces due to retraction artefact, the distinction is not always straightforward, as illustrated by some published photographs of tumour budding. 1, 38 Moreover, MP features are sometimes also present at the leading edge of a tumour. 11 However, tumour buds by definition emerge from more well-established malignant glands and therefore should lie in close proximity to them, whereas MP clusters are more widely infiltrative and can extend far beyond conventional glandular components in a tumour. Additionally, observation of reversed polarity is a helpful clue in identifying MP features. One study found that MP CRC were more likely than conventional CRC to demonstrate tumour budding. 7 Also of note is the so-called 'poorly differentiated cluster', a recently described finding in CRC 39 with a similar histological appearance to micropapilla formation. This may, in fact, represent the same biological phenomenon. 33 Our study also identified a 'background' morphology often seen in tumours with MP features. Even well away from MP areas, these tumours were composed of cribriforming malignant glands, often forming large cystic spaces filled with dirty necrotic debris. This morphology tended to persist in nodal and distant metastases, more so even than MP morphology. MP features are almost always seen in lymph node metastases from sites such as the breast, 40 but our findings and those of other researchers show that this phenomenon is only sometimes seen in colon tumours. 5, 9 While cribriforming glands and large cystic glands with necrosis can certainly be seen in conventional CRC, the identification of these findings should heighten the search for MP features elsewhere and, if seen on biopsy, may predict their presence on resection. Additionally, somewhat similar features have been reported in microsatellite-stable tumours with CpG island methylation (so-called 'cribriform comedo-type adenocarcinomas'), 1 but MP morphology was not mentioned in the original description of this CRC subtype. Given the characteristic morphology of these tumours, both in MP areas and elsewhere, a unique molecular phenotype might be expected. One previous study 8 analysing molecular features of 60 MP CRC found a significant increase in TP53 mutation and a trend towards increased KRAS and BRAF V600E mutation compared to conventional cases. Additionally, nearly all their cases were microsatellite-stable or showed low MSI. The results of our molecular analysis were similar, with 35% of cases harbouring KRAS mutation, 13% of cases harbouring BRAF V600E mutation and no cases showing MSI. In three tumours we were able to analyse both MP and cribriform areas, with no difference in molecular phenotype. Considering that KRAS and BRAF mutations are believed by some to impart a worse prognosis, 42, 43 and MSI a better prognosis, 44 the molecular findings in this subtype of CRC are not surprising. Given the current push towards subtyping CRC based on molecular properties in order to optimize therapy and manage prognostic expectations, 45 it seems likely that additional molecular characterization, potentially with unique defining genetic alterations, will be discovered in this carcinoma subtype in the future. Along these lines, Lee and colleagues 10 observed increased expression of the stem cell markers SOX2 and NOTCH3 in MP CRC.
While MP carcinoma is associated with higher disease stage and increased rates of lymph node metastasis, an underlying mechanism for this behaviour has not been identified. One possibility is EMT, which has been associated with increased metastatic potential in other carcinomas. When examined, most of our cases showed loss of epithelial markers (AE1/AE3 and E-cadherin) and gain of mesenchymal markers (vimentin). Most also showed nuclear localization of SMAD4; while this finding is not specific and has been reported in CRC previously, 46 it suggests the activation of transforming growth factor b signalling, which is known to be an important event promoting EMT. 31, 47, 48 Our combined immunohistochemistry findings indicate that EMT is characteristic of MP CRC and may play a role in its propensity to present with advanced, metastatic disease. Interestingly, EMT also plays a role in tumour budding, which can mimic MP features, as above. 24 Colorectal MP carcinoma is an aggressive neoplasm with a propensity towards metastasis. These tumours may harbour KRAS or BRAF mutation and are typically microsatellite-stable. Given the overall poor prognosis of this tumour due to presentation at advanced stage, its recognition is crucial. Further clinical and molecular studies will hopefully implicate additional genetic alterations and refine management of patients with this disease.
